FDA approves quarterly siRNA for myasthenia gravis
-
By
-
Mouj Hijazi
-
November 19, 2026
-
2 min
By
Mouj Hijazi
November 19, 2026
Phase 3 findings show improvements in physical function and skin disease activity.
August 28, 2026
“Doctors rely on this evidence, patients rely on this evidence, and if that evidence is not there, it’s going to lead to a lot of uncertainty."
September 22, 2026